rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Neuphoria Therapeutics Inc.

NEUP · Nasdaq

Health CareBiotechnologyNot moving yetNeurotech

NEUP stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 21.1% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$3.3M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
20 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.2MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders20+5 on the quarter
New · exited7 · 2
Reported value$8.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Lynx1 Capital Management LPunchanged · filed 12 Aug 2026875,328$3.8M00.0%
AdvisorShares Investments LLCadded · filed 11 Aug 2026252,909$1.1M+97,542+62.8%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 2026173,488$758K+173,488
Shay Capital LLCadded · filed 14 Aug 2026155,822$681K+4,812+3.2%
Balyasny Asset Management L.P.added · filed 14 Aug 2026142,228$622K+450.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202672,559$317K+53,228+275.4%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202649,516$216K-2,491−4.8%
Ikarian Capital, LLCunchanged · filed 14 Aug 202647,443$207K00.0%
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 202633,806$148K+33,806
ADAR1 Capital Management, LLCunchanged · filed 14 Aug 202630,000$131K00.0%
31 Dec 2024 – 30 Jun 2026
71420Dec 24Jun 25Sep 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Alan Fisher Company insiderDirector · last 20 Jan 20260 · 0
David Ian Wilson Company insiderDirector · last 20 Jan 20260 · 0
Jane Ryan Company insiderDirector · last 20 Jan 20260 · 0
Peter Miles Winston Davies Company insiderDirector · last 20 Jan 20260 · 0
Lynx1 Capital Management LP Company insider10% owner · last 21 Oct 20251 · 0
Spyros Papapetropoulos Company insiderPresident and CEO · last 27 Aug 20250 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2026 · to 30 Jun 2026-58.9%
Share count trendFY 2026 · to 17 Sep 20260.0%
Cash and equivalentsFY 2026 · to 30 Jun 2026$19.9M

Analyst forecasts

No analyst forecasts yet.